A study published in the National Library of Medicine in the United States found that the use of nicotine-free electronic cigarettes is more effective in promoting smoking cessation than nicotine delivery systems, based on a one-year double-blind randomized trial. The abstract of the paper is compiled by 2FIRSTS below.
The aim of this study was to determine whether using electronic cigarettes to help quit smoking is beneficial for improving the lung health of chronic smokers. The effectiveness of electronic cigarette support in successful smoking cessation attempts was also studied. A total of 210 smokers (78 females) participated in an early lung cancer screening program and were divided into three groups: nicotine electronic cigarette plus support, non-nicotine electronic cigarette plus support, and support only. The results showed that participants in the nicotine electronic cigarette group significantly and rapidly reduced their daily smoking intake, but they relapsed more frequently than the other two groups. Conversely, participants in the other two groups had similar daily consumption levels at both assessment points. Among the participants who quit smoking, only 12 reported coughing, while 48% of current smokers had lung symptoms. Our study suggests that in the long run, using non-nicotine liquids may be beneficial for reducing smoking and may be considered a good option in clinical settings.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
